Anavex Life Sciences Corp reports results for the quarter ended March 31 - Earnings Summary

Anavex Life Sciences

31/07/2026 02:01

Anavex Life Sciences Corp AVXL.OQ reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -13 cents.  The lone analyst forecast for the quarter was for a loss of 7 cents per share. 
Reported revenue was zero​; analysts expected zero. 
Anavex Life Sciences Corp's reported EPS for the quarter was a loss of 6 cents​.
Anavex Life Sciences Corp shares had fallen by 3.9% this quarter and lost 30.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 6.7% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Anavex Life Sciences Corp is $20.00, about 86.5% above its last closing price of $2.70
This summary was machine generated from LSEG data July 31 at 01:01 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Mar. 31 2026 
-0.07
-0.06
Beat
Dec. 31 2025 
-0.11
-0.06
Beat
Sep. 30 2025 
-0.15
-0.11
Beat
Jun. 30 2025 
-0.14
-0.16
Missed